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Abstract
The zinc importer LIV-1, also known as ZIP6, is widely distributed, mainly in
hormonally controlled tissues such as breast, prostate, kidney, and pituitary. Attention
has focused on its role in breast cancer, especially its regulation by estrogen and
epidermal growth factor (EGF) and its link to the Epithelial–Mesenchymal Transition
(EMT) marker, E-cadherin (CDH1). EMT is important for tumor progression and
metastasis and therefore a potential target for cancer therapy. CDH1 expression is
under complex control, including by two transcriptional repressors, Snail and Slug.
Similar to CDH1, MMP-9 is also a cancer progression marker. Elevated MMP-9
expression has been linked to increased metastasis and tumor stage.
In the present study, we investigated the relationship between LIV-1 and CDH1
in prostate cancer cell lines, LNCaP and DU145. Cells were treated with or without
10ng/ml EGF for 24 hours, and the mRNA and protein expressions of LIV-1 and
CDH1 were analyzed by two-step RT-PCR and western blot, respectively. In both
DU145 cells and LNCaP cells, EGF induced LIV-1 protein expression by about 20%
and decreased CDH1 mRNA and protein by approximately 40%. However, no
significant change in LIV-1 mRNA was seen with EGF treatment, indicating a
post-transcriptional mechanism. EGF also promoted proliferation in the two cell lines.
LIV-1 shRNA transfection was used to understand whether LIV-1 knockdown
would influence CDH1. LIV-1shRNA vectors decreased the LIV-1 mRNA and
protein expression in DU145 cells by around 40%. The effects of LIV-1 knockdown
on CDH1, Snail, Slug and MMP-9 mRNA expression were also measured. LIV-1
xi

knockdown increased CDH1 mRNA (80%), while it decreased the expression of Snail
mRNA (60%) and MMP-9 mRNA (40%) significantly. There was no significant
change observed in Slug mRNA expression. It was also found that LIV-1 knockdown
inhibited cell proliferation of DU145 cells, suggesting that LIV-1 may contribute to
the EGF-stimulated cell proliferation.
In summary, this study established an inverse relationship between LIV-1
expression and CDH1 in prostate cancer cells. LIV-1 could be a potential biomarker
and a therapeutic target in prostate cancer progression and metastasis study.

xii

Chapter 1: Literature Review
1.1 Zinc in human physiology
Zinc is present universally in body tissues and fluids. The total body zinc content
has been estimated to be 30 mmol (2 g). Zinc in skeletal muscle accounts for
approximately 60% of the total body zinc content and bone mass for approximately
30%. The concentration of zinc in lean body mass is approximately 0.46mmol/g (30
mg/g). Plasma zinc has a rapid turnover rate and it represents only about 0.l% of total
body zinc content. This level is under tight homeostatic control. High concentrations
of zinc are found in the choroid of the eye as well as in prostatic fluids. [1]
Zinc is necessary for normal biochemical functions in association with proteins,
such as catalytic, structural and regulatory. [2] In terms of catalytic effects, zinc is
required by more than 50 enzymes. Removal of zinc from zinc metalloenzymes can
cause activities to decrease and adding back zinc can restore enzyme activities. The
structural role of zinc was established by the discovery of the zinc finger motif, which
is contained in all kinds of proteins, such as those participating in cellular
differentiation or proliferation, signal transduction, cellular adhesion, or transcription.
Zinc is also involved in maintaining structures of some enzymes, for instance, CuZn
superoxide dismutase, where copper is at the active site and zinc maintains the
enzymatic structure. Another essential zinc function is to regulate gene expression.
More than 2000 transcription factors need zinc to maintain their structural integrity
and ability to bind to DNA. [2]
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Zinc is essential for various physiological processes, such as cell proliferation,
reproduction, immune function and defense against free radicals. [3] The symptoms
of zinc deficiency include impaired growth, loss of hair, thickening and
hyperkeratinization of the epidermis, and testicular atrophy in humans. Severe zinc
deficiency can affect various organs, such as the gastrointestinal, central nervous,
immune, skeletal and reproductive systems. [4] Chronic diseases, such as
gastrointestinal disorders, renal disease, sickle cell anemia, some cancers, pancreatic
insufficiency and autoimmune arthritis, have been shown to cause suboptimal zinc
status in humans. [4]
Zinc deficiency increases lipid peroxidation in mitochondrial and microsomal
membranes which makes zinc beneficial to the integrity of the subcellular organelles.
Since zinc has protective efficiency in regulating the activities of antioxidant
enzymes, thyroid hormones, and liver marker enzymes, it is also essential to normal
cell physiological functions. [5]

1.2 Zinc in cancer
The role of zinc in cancer has received increasing attention. The link between zinc
deficiency and cancer progression has been established in human, animal and cell
culture studies. [3] It was found as early as 1976 that primary osteosarcoma patients
had elevated serum zinc, while patients with metastases had depressed zinc levels. [6]
Zinc is essential to various enzymes and transcription factors that regulate key
cellular functions. [7] Insufficient accessibility to intracellular zinc could result in a
2

decrease of activities of those zinc-dependent proteins involved in the maintenance of
DNA integrity and may contribute to the development of cancer. [7] For instance,
zinc is required for site-specific DNA binding and proper transcriptional activation of
the tumor suppressor protein p53. Both insufficient zinc and excess zinc could cause
p53 to miss-fold and result in functional loss. [7] Zinc deficiency has also been shown
to upregulate expression of another tumor suppressor protein nuclear factor κB
(NF-κB) in rat glioma C6 cells. [5] It has been suggested that a decrease in cellular
zinc alone causes DNA damage and impairs DNA damage response mechanisms,
resulting in a loss of DNA integrity and the potential for increased cancer risk. [5]
There are many reports of abnormal zinc levels in serum and malignant tissues of
patients with various types of cancer. In breast cancer, for instance, tissue zinc
concentrations were increased greatly, however, in kidney carcinoma, concentrations
were decreased markedly. [8] Similar to kidney, zinc content in malignant prostate
tissues are significantly lower than the levels found in normal prostate and benign
prostate hyperplasia. [9]
The reduced ability of malignant cells to accumulate zinc is one of the most
important factors in the development and progression of prostate malignancy. [10]
The peripheral zone glandular secretory epithelium in the prostate accumulates
extraordinarily high levels of zinc, three to ten times higher than that of other soft
tissues. This is special because mammalian cells generally need to avoid the
accumulation of high zinc, especially mobile reactive zinc which is toxic. However in
the peripheral zone of the prostate, an especially high mitochondria zinc level is
3

essential to inhibit m-aconitase activity which can prevent the oxidation of citrate and
lead to the accumulation and secretion of citrate. [10] The suppressed citrate oxidation
caused by inhibition of m-aconitase is lethal in other mammalian cells, since it
eliminates the coupled energy production that normally occurs from Krebs cycle
oxidation. [10] Without citrate oxidation, 14 Adenosine-5'-triphosphate (ATP) are
produced from one glucose, compared with 38 ATP when citrate oxidation exists. The
malignant prostate cells become energy-efficient cells in the absence of high zinc
concentration, in contrast to the energy-inefficient, citrate-producing cells. Additional
energy required for the malignant cell to perform its potential malignant activities is
produced without the inhibition of zinc on m-aconitase activity. [10]
Findings of an association between zinc and prostate cancer risk have been
inconsistent. One study of vitamin and mineral supplement use found that zinc
supplements had a protective function for prostate cancer. [11] In a population-based
case-control study, little association was found between dietary zinc intake and
prostate cancer. [12] However, in one follow-up study, it was found that chronic zinc
oversupply could increase the risk of advanced prostate cancer. [13] Similarly,
another case-control study done in Italy found a direct association between high zinc
intake and prostate cancer risk, particularly for advanced cancers. [14] Different
methods of acquiring dietary zinc intake data could affect the results but it is still not
clear if zinc supplements can reduce or elevate prostate cancer risk.

4

1.3 zinc transporters
There are two families of zinc transporters in humans. One is the ZnT (SLC30)
family of transporters with 10 members, which carry zinc from the cytoplasm into the
organelles or outside to the extracellular space. The other is the ZIP (SLC39) family
with 14 members, which are responsible for taking zinc from the extracellular space
or organellar lumen into the cytoplasm. [15]
Some of the zinc transporters have wide tissue distributions, such as ZnT1 and
ZIP1. But many others have restricted tissue expressions. For instance, ZnT5 mRNA
is highly expressed in human endocrine pancreas, ovary, prostate, and testis tissues.
Meanwhile, the liver, brain, and small intestine have the highest levels of ZnT6
mRNA over other tissues or organs. In addition, mRNA and protein concentrations of
ZnT6 differed within a tissue, which suggested some undefined processing step. [16]
Several ZnT and ZIP family members are major factors in regulation of zinc
homeostasis, such as ZnT1, ZIP4, and ZIP5 in intestinal zinc transport, ZIP10 and
ZnT1 in renal zinc reabsorption, and ZIP5, ZnT2, and ZnT1 in pancreatic release of
endogenous zinc. Many of them are also involved in other physiological functions, for
example, ZnT2 in lactation, ZIP14 in the hypozincemia of inflammation, ZIP6, ZIP7,
and ZIP10 in metastatic breast cancer, and ZnT8 in insulin processing and as an
autoantigen in diabetes. [15]
The ZnT4 Zn transporter, expressed in breast epithelial cells, is responsible for the
inherited zinc deficiency observed in lm (lethal milk) mice, showing that ZnT4 is
required to supply zinc in breast milk. In addition, human breast-fed infants studies
5

have also revealed a potential role of ZnT2 in the transport of zinc to milk.
The mRNA and protein of ZIP4 were regulated in response to zinc availability and
mutations in ZIP4 cause acrodermatitis enteropathica, a rare recessive-lethal human
genetic disorder. [17] A number of studies have found that the expression levels of
zinc transporters in human tumors correlate with their malignancy, suggesting that
alteration of intracellular zinc homeostasis can contribute to the severity of cancer.
These findings indicate that regulation of zinc homeostasis by zinc transporters plays
important roles, disruption of which may lead to disease states. [4]

1.4 Zinc transporters in cancer
Many zinc transporters, such as ZIP4, ZIP6, ZIP7, and ZIP10, have been shown to
be aberrantly expressed in various cancers. For instance, the expression of ZIP4 is
activated in pancreatic and hepatocellular cancers. [18-21] In a nude mouse model
with orthotopic xenografts, silencing of ZIP4 by RNA interference in pancreatic
cancer cell lines reduced incidence of tumor metastasis, downsized the tumor grade,
and significantly increased their survival rate. [18] Knockdown of ZIP4 in mouse
Hepa cells significantly activated apoptosis and modestly slowed progression from
G0/G1 to S phase when cells were released from hydroxyurea block into
zinc-deficient medium. It was shown that knockdown of ZIP4 in Hepa cells depressed
their migration; moreover ZIP4 overexpression in Hepa cells and MCF-7 cells
enhanced migration. [19] In another study, treatment with physiological
concentrations of zinc increased the abundance of ZnT-1 mRNA in a rat insulinoma
6

and two human ductal adenocarcinoma cell lines but not in normal human islet cells.
[22] However, the more significant correlations were found between zinc transporters
and breast and prostate cancers.

1.4.1 Zinc transporters and breast cancer
In the United States, breast cancer is the most common malignant tumor expected
to occur in women, accounting for 28% of incident cases. It is also the second leading
cause of cancer death in women, following lung and bronchus cancer. [23] ZIP6,
ZIP7, and ZIP10 are all suspected to be involved in metastatic breast cancer. [20, 21,
24, 25]
ZIP7 expression can be enhanced by exogenous zinc in a tamoxifen-resistant
breast cancer model (TamR cells). Knockdown of ZIP7 with small interfering RNA
terminated the activation of epithelial growth factor receptor (EGFR)/IGF-I
receptor/Src signaling. [25] In cancer, the abnormal balance between cell death and
survival makes cancer cells survive under condition that would normally induce
apoptosis. EGF provides a strong cell survival signal and offers antiapoptotic ability
to promote cancer cell survival in inappropriate environments. [26]
The zinc transporter ZIP10 plays an essential role in the migratory activity of
highly metastatic breast cancer as well. Screening of clinical samples for ZIP10
mRNA expression indicated that ZIP10 was significantly correlated with the
metastasis of breast cancer to the lymph nodes. In addition, the expression of ZIP10
mRNA was higher in the invasive and metastatic breast cancer cell lines compared
7

with less metastatic ones. In in vitro cell migration assays, the depletion of ZIP10 and
intracellular zinc inhibited the migratory activity of invasive and metastatic breast
cancer cell lines MDA-MB-231 and MDA-MB-435S. [24]
The zinc transporter LIV-1, also known as ZIP6, is estrogen regulated and present
in greater concentration in estrogen receptor–positive breast cancers as well as in
tumors that spread to the lymph nodes. [27] LIV-1 has been associated with signal
transducer and activator of transcription 3 (STAT3), a molecule linked with breast
cancer progression. This association was first observed in zebrafish embryos where
LIV-1 was shown to be the downstream target of STAT3 and essential for the nuclear
localization of another transcription factor, Snail, which causes loss of cell adhesion
by reducing adherence proteins. [21] Further evidence for an involvement of LIV-1
with Snail was provided by the observation that LIV-1 siRNA reduced HeLa cell
invasion via a Snail pathway. [20]

1.4.2 Zinc transporters in prostate cancer
In the United States, prostate cancer is the most common malignant tumor
expected to occur in men, accounting for 28% of incident cases. It is also the second
leading cause of cancer death in men, after lung and bronchus cancer. [23]
Growth of human prostate cancer cells, LNCaP and PC-3, was inhibited by zinc
treatment in a dose-dependent manner. [28] Up-regulated gene expression of
metallothioneins (MTs) and ZnT1 in both cell lines were observed after zinc
treatment. Since BPH (Benign prostatic hyperplasia) accumulates much more zinc
8

than prostate malignant tissue, the overall balance of zinc is decreased in the prostate
cancer cells. It was not surprising that compared with BPH, prostate cancer tissues
expressed significantly lower levels of ZnT1 gene. [28] ZnT4 expression also reduced
in malignant prostate tissue compared to normal and benign prostate tissue. [29]
Similarly, mRNA and protein expressions of the zinc uptake transporter, ZIP1, are
significantly down-regulated in prostate adenocarcinomatous tissue compared with
normal prostate tissue. These changes occur early in malignancy and are maintained
through its progression in the peripheral zone. [30] However, overexpressed ZIP1 in
PC-3 prostate cancer cells results in significant inhibition of NF-kB activity and
induced secretion of NF-kB-controlled tumorigenic cytokines, such as IL-6 and IL-8.
NF-kB-regulated genes have an established role in malignant transformation,
metastatic progression of prostate cancer, and resistance to therapeutic regimens.
Moreover, ZIP1 overexpression induces suppression of prostate tumor growth in a
xenograft model. [31] It has been shown that both ZIP2 and ZIP3 are down regulated
in malignant cells in situ as demonstrated for ZIP1. [32] In contrast to the ZIP1
localization at the basolateral membrane, ZIP2 and ZIP3 transporter proteins were
localized predominantly at the apical cell membrane. It was proposed that ZIP2 and
ZIP3 appeared to be associated with the re-uptake of zinc from prostatic fluid. [32]

1.5 The zinc importer LIV-1 and cancer
The zinc importer LIV-1 is estrogen-regulated and expressed universally, mainly
in hormonally controlled tissues such as breast, prostate, placenta, kidney, pituitary
9

and corpus callosum. [27] One investigation in human breast cancer patients found
that LIV-1 mRNA and protein expression levels are weakly correlated, indicating
posttranscriptional regulations. [33] In contrast to the usual finding that LIV-1 is
found in increased amounts in estrogen receptor–positive breast cancer as well as in
tumors that spread to the lymph nodes[27], another study found that LIV-1 mRNA
had a trend to lower expression in tumors with lymph node metastasis, although this
was not significant at the 5% level. [33] Meanwhile high LIV-1 protein expression
seems to be associated with a longer relapse free and overall survival in breast cancer
patients with invasive ductal carcinoma. A negative correlation of LIV-1 protein but
not mRNA levels with tumor size, grade and stage reflected an association of LIV-1
protein expression with less aggressive tumors. [33]
LIV-1 has been identified as a gene whose expression is stimulated by estrogen
treatment in MCF-7 and ZR-75 breast cancer cells. [27] An investigation of LIV-1
expression in clinical breast-tumour populations revealed its significant correlation
with estrogen receptor status. [27] LIV-1 mRNA correlation with the estrogen
receptor and its regulation by the receptor have been reported in several studies. [27,
33]
LIV-1 has been shown to contain a novel potential metalloprotease motif similar
to that in the MMPs (matrix metalloproteases), which have an important and
well-documented role in metastasis. [34] Recently, it was found that overexpression
of LIV-1 in prostate cancer ARCaPE cells resulted in elevated MMP-2 and MMP-9
proteolytic enzyme activities. [35]
10

In zebrafish gastrula organizer, LIV-1 was shown to control
epithelial-mesenchymal transition (EMT) by being a downstream target of the
transcription factor STAT3, which has a proven role in the development of cancer.
LIV-1 was essential for the nuclear localization of the zinc finger transcription factor
Snail, a master regulator of EMT. [21] The significant association between LIV-1,
Snail and CDH1 suggested a link between the LIV-1 and EMT in breast cancer.

1.6 EGF and EGFR
Cancer cells have a characteristic ability to survive under conditions that would
normally induce apoptosis. Epidermal growth factor (EGF) provides a strong cell
survival signal and cancer cells promote their survival in inappropriate environments
through this type of survival signaling. [36]
The EGF receptor (EGFR) is a transmembrane protein that regulates the
intracellular effects of ligands such as EGF and transforming growth factor-α
(TGF-α). [37] With ligand binding to the EGFR extracellular domains, the proportion
of dimerized receptor increases and the enzymatic activity of its intracellular tyrosine
kinase domain is induced dramatically. The EGFR exerts its function in the cellular
environment directly or indirectly through its tyrosine kinase activity. [37] Increased
expressions of the ligands and/or receptors, as well as ligand-independent receptor
activation, have been found in many epithelial cancers, especially gliomas and breast,
pancreas, and liver carcinoma. Human carcinomas frequently express high EGFR and
this has been associated with a more invasive clinical behavior. Moreover, activation
11

of high levels of EGFR in nonmalignant cell lines can lead to a transformed
phenotype. [38]
Multiple signalling pathways can be activated by EGFR, such as the PI3K/AKT,
RAS/ERK and JAK/STAT pathways. [26] STAT3 and AKT activation correlated
markedly with EGFR status in malignant astrocytic gliomas. [39] A significantly
positive correlation between nuclear STAT3 and EGFR expression in breast cancers
was also reported. [36] STAT3 activation has been shown to play a role in
oncogenesis and activated STAT proteins are found in human cancer. STAT proteins
constitute a family of transcription factors that are activated by cytokine and
non-cytokine receptors. Activation of STAT causes tyrosine phosphorylation,
dimerization and translocation from the cytoplasm to the nucleus. [36]

1.7 EMT and E-cadherin (CDH1)
EMT is a rapid and mostly reversible change of cell phenotype. [40] During this
process, epithelial cells loosen their cell–cell adhesion structures such as adherens
junctions and desmosomes, modulate their polarity and rearrange their cytoskeleton.
As a result, they become isolated, motile and resistant to apoptosis. [40] EMT has
been recognized as a critical phase of embryonic development in animal species. [41]
Such EMT-like processes are also evoked in tumor progression and metastasis. [40]
Many in vitro studies show that various carcinoma cell lines undergo EMT or partial
EMT.

EMT leads to the dissemination of single carcinoma cells from the sites of the
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primary tumors. More generally, EMT might be involved in the dedifferentiation
process that causes malignant carcinoma. [41]
Several signal-transduction pathways for EMT have been identified based on
research conducted in embryonic model systems and in normal and transformed cell
lines, including the activation of several receptor tyrosine kinases and transforming
growth factor-β receptors. [42] Transcriptional repressors of CDH1 are induced in
these pathways, leading to the loss of the epithelial phenotype. Declining expression
of CDH1 mRNA and protein are hallmarks of EMT, both in embryonic development
and in cancer progression. [42] Down-regulation of CDH1 is associated with cell–cell
dissociation and invasion in pancreas, prostate and mammary gland mouse cancer
models. [40] CDH1 is required for the maintenance of stable junctions and regarded
as one of the hallmarks of the epithelial phenotype. In epithelial cells, early contacts
are mediated by CDH1 molecules that cluster into small junctional complexes, which
then expand to establish stable adherens junctions and promote the formation of
desmosomes. Loss of CDH1 expression seems to be strongly involved in EMT since
there is a direct link between lack of CDH1 production and loss of the epithelial
phenotype. [41]
Another cadherin, N-cadherin, by contrast, is produced in some carcinoma cells
that have lost CDH1 and, in these cells, N-cadherin appears as a weak intercellular
adhesion system. [41]
Specific transcription factors, in particular Snail (Snail1), Slug (Snail2), Twist,
SIP1/Zeb and E47, negatively regulate CDH1 expression. These factors participate in
13

most physiological EMT situations, and their overexpression in epithelial cells usually
induces EMT. [40]

1.8 Snail and Slug
During tumor progression, various mechanisms can inactivate or silence CDH1,
such as somatic mutations, promoter hypermethylation, histone deacetylation, and,
importantly, transcriptional repression. Several EMT-inducing developmental
regulators repress CDH1 transcription by binding with specific E-box domains in the
proximal CDH1 promoter. [42] Most prominent are the Snail-related zinc-finger
transcription factors Snail and Slug, the repressors ZEB-1 and ZEB-2. [42]
Endogenous Snail protein is present in invasive mouse and human carcinoma cell
lines and tumors in which CDH1 expression has been lost. Epithelial cells that
overexpressed Snail showed a fibroblastoid phenotype and acquired tumorigenic and
invasive properties. [43] In pancreatic cancer, Snail and Slug are expressed, but not in
normal tissue. [44]. It was also found Slug and Snail correlated negatively with CDH1
in transformed breast cell lines. [45] Inconsistent correlations between Snail
expression and tumor progression in human breast cancer have been seen in another
study where reduced Snail expression corresponded with higher tumor grades. [46]

1.9 MMP-9
Controlled degradation of extracellular matrix (ECM) is critical for the growth,
invasion, and metastasis of malignant tumors, and for tumor-induced angiogenesis.
14

[47] Because of their capacity to degrade ECM, resulting in migration of endothelial
cells, matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9 are known
to play a role in angiogenesis, tumor growth and metastasis. [48] Both MMP-2, also
known as gelatinase A, and MMP-9, also known as gelatinase B, are
cancer-associated, secreted, zinc-dependent endopeptidases, belonging to the
gelatinase subgroup of MMP. [49] 72-kDa MMP-2 is expressed in various cell types,
such as osteoblasts, monocytes, and different types of transformed cells. 92-kDa
MMP-9 is produced by, for instance, normal alveolar macrophages, osteoclasts,
invading trophoblasts, and several types of transformed cells. [49]
Besides extracellular matrix, MMP-2 and MMP-9 cleave many different targets,
such as cytokines, growth factors and cytokine/growth factor receptors which in turn
regulate key signaling pathways in cell growth, migration, invasion, inflammation and
angiogenesis. [49] Expression of MMP-9 is induced at the transcriptional level, by
growth factors and cytokines, oncogenes, hormones, and contact to the ECM. For
instance, inhibition of the tumor repressor protein NF-κB reduced the expression of
MMP-9 in vascular smooth muscle cells. [50] It was found in the MDCK epithelial
cell line that MMP-9 transcription is also activated in response to Snail
overexpression. [51]
Elevated levels of MMP-2 and/or MMP-9 have been reported in many kinds of
cancers, such as breast, brain, ovarian, pancreas, colorectal, bladder, prostate and lung
cancers. Since they are overexpressed in a variety of malignant tumors and their
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expression and activity are often associated with tumor aggressiveness and a poor
prognosis, they are regarded as cancer biomarkers. [49]
MMPs have been shown to play a role in the processes of tumor angiogenesis,
tumor growth and metastasis, albeit that these processes are intermingled with each
other. [48] Elevated MMP-9 expression has been linked to increased metastasis and
tumor stage in a number of studies, e.g. malignant versus benign breast tumors and
advanced versus benign ovarian tumors. In several invasive cell lines, MMP-9
expression was increased compared to non-invasive counterpart. [48] Also MMP-9
overexpression increased the incidence of metastatic diseases in immunocomprized
mice. [48]
The relation between MMP-9 and CDH1 has been investigated but is still not
clear. One study in epithelial ovarian cancer cells showed that MMP-9 was involved
in EGF-dependent down-regulation of CDH1 and recombinant MMP-9 or transient
expression of MMP-9 was sufficient to reduce CDH1 levels in the absence of EGF.
[52] Incubation of epithelial ovarian carcinoma cells with exogenous MMP-9
catalyzed CDH1 ectodomain shedding, suggesting posttranslational modification of
CDH1 function via MMP-9. [53] The soluble CDH1 fragment thus released inhibits
CDH1 functions in a paracrine way. [54] However, some other studies indicated that
CDH1 might be the upstream regulator of MMP-9. In invasive bronchial BZR tumor
cells, expression of CDH1 resulted in decreased MMP-9 both at the mRNA and at the
protein levels. [55]

16

Chapter 2: Hypotheses
Hypothesis I:
EGF treatment will induce LIV-1 expression and decrease CDH1 expression in
prostate cancer cell lines, DU145 and LNCaP.

Hypothesis II:
EGF treatment will stimulate growth of these cells.

Hypothesis III:
Knockdown of LIV-1 will increase CDH1 expression in DU145 cells. CDH1
repressors, Snail, Slug and MMP-9 may play essential roles in this process.
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Chapter 3: Materials and Methods
3.1 Cell Culture and Subculture:
Androgen-independent human prostate cancer cells (DU145) and
androgen-responsive human prostate cancer cells (LNCaP) were obtained from the
American Type Cell Culture Collection (ATCC, Rockville, MD) and grown as
recommended in 5% CO2 at 37˚C and 95% humidity. The cells were maintained in
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal
bovine serum. T-75 flasks were used to maintain DU145 and LNCaP cells in 15 ml of
media. When the cells reached confluency, the media was removed and the cell
monolayer was rinsed with 5 mL of Phosphate Buffered Saline (PBS). To detach the
cells, 3 ml of 1XTE (0.05% Trypsin / 0.53 mM EDTA) was added to the cell layer
and incubated for 5 minutes. Once the cells were observed to be detached, 7 ml of
media was added to the cell suspension. This 10 ml of cell suspension was next
aliquoted to two T-75 flasks. Fresh media (10 ml) was added to each flask after the
division.

3.2 EGF treatment
DU145 and LNCaP cells were grown in T-25 flasks until they reached an
approximately 60% confluency. Cells were incubated in serum-free RPMI for 24hrs.
Serum-free RPMI with or without 10ng/ml of EGF (Sigma, St. Louis, MO) was used
for another 24 hours and then RNA and proteins were extracted. Three flasks were
assigned to each treatment group---non-EGF as control, and 10 ng/ml EGF.
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3.2 Transfection
pLKO.1-puro vector plasmids (Sigma, St. Louis, MO) with short hairpin RNA
(shRNA) specifically targeting the LIV-1 gene were utilized for the transfection
process. pLKO.1-puro non-target shRNA control vector plasmids were used as
control. The pLKO.1-puro shRNA plasmids contained a puromycin selection marker
for stable transfection. The whole plasmid with shRNA targeting LIV-1 was
transfected into DU145 cells with Fugene HD Transfection reagent (Roche Applied
Science, Indianapolis, USA).

DU145 cells were plated in T-25 flasks with the

confluency around 80%. Fugene HD transfection reagent, opti-MEM (diluent for
DNA) and LIV-1shRNA plasmids were taken out, and adjusted to room temperature.
Plasmids (2 ug) were diluted into 100 uL opti-MEM. 9uL of Fugene HD transfection
reagent was added to the plasmids-opti-MEM mixture to make the ratio between
transfection reagent and plasmids 9:2. The transfection complex was mixed and
incubated for 15 to 40 minutes then added to the prepared DU145 cells. After 3 days
incubation, media were replaced with normal growth media. Ten ug/ml puromycin
(Fisher Scientific, Pittsburgh, PA) was added to select the cells with plasmids before
the RNA and proteins were extracted.
A titrating test was used to determine the concentration of puromycin for
transfection selection. Untransfected DU145 cells (2 x 105 ) were plated in each well
of a 6-well plate containing 3 ml of the growth media with increasing concentrations
of puromycin (0, 5.0, 7.5, 10.0 and 12.5 µg/ml). Fresh selective media were replaced
after 2 days. After two additional days, the percentages of surviving cells were
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counted. Ten and 12.5 ug/ml puromycin were able to kill 100% of the cells, so the
concentration of puromycin used for selection was determined to be 10 ug/ml.

3.3 Cell Proliferation Assay
Cell numbers were routinely quantified with a hematocytometer. Cells were
detached with trypsin. A 50 ul cell suspension, 400 ul PBS and 50 ul trypan blue
(Sigma, St. Louis, MO) were mixed in a microcentrifuge tube and left at room
temperature for 5 minutes. A small amount of the trypan blue-cell suspension was
transferred to a chamber on the hematocytometer. After counting the cells, about 5 x
104 cells were inoculated in each well of a 96-well plate and returned to the incubator.
Before the cell proliferation was tested, 120 ul of a mixture of fresh medium and
CellTiter-Blue reagent (Promega Corporation, Madison, WI) in a ratio of 100:20 were
used to replace the media in each well. After incubation at 37 °C for 1 hour, the
96-well plate was transferred to a micro-spectrophotometer and the florescence values
were read using an excitation wavelength at 560 nm and emission at 590 nm.

3.4 RNA extraction
Total cellular RNA was extracted from DU145 and LNCaP cells grown in T-25
flasks using the Trizol reagent (Invitrogen, Carlsbad, CA). The media were decanted
off and cells were rinsed with 3 ml of PBS. 1XTE (1.5 ml) was next added to detach
the cells. The detached cells were poured into labeled 15 ml polypropylene tubes and
centrifuged at 1000 rpm for 3 minutes. After the cell pellets were obtained, 500 µl of
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Trizol was added to each tube to dissolve the cell pellets. The cell pellets were
vortexed and transferred to micro-centrifuge tubes and 250 ul chloroform was added.
The tubes were vortexed and incubated on ice for 3 minutes and then were further
centrifuged at 4°C in a micro-centrifuge (Eppendorf, New York, NY) at 10,000 X g
for 21 minutes to separate the aqueous and the organic phases. The dissolved RNA in
the aqueous phase was carefully pipetted out into a fresh micro-centrifuge tube. To
precipitate the RNA from the aqueous phase, 500 µl isopropanol (Fisher Scientific,
Pittsburgh, PA) was added and mixed. After incubation overnight at -20°C, the
precipitated RNA was obtained through centrifuging at 10,000 rpm at 4°C for 15
minutes. To get rid of the contaminating salts and proteins, the pellets were then
washed with 500 µl 75% ethanol, vortexed, and centrifuged at 10,000 rpm for 5
minutes. The pellets were air dried for 10 minutes to evaporate the alcohol. The dry
RNA pellets were then dissolved in Diethylpyrocarbonate (DEPC)-treated water
(Fisher Scientific, Pittsburgh, PA). They were stored at -80°C if they were not to be
processed immediately for experiments.

3.5 RNA concentration measurements
The concentrations of RNA in each sample were estimated using a NanoDrop
1000 Spectrophotometer. (NanoDrop products, Wilmington, DE) Sample
concentration in ng/ul was based on absorbance at 260 nm and the selected analysis
constant 40 ng-cm/ul. The ratio of absorbance at 260 and 280 nm was used to assess
the purity of RNA. A ratio close to 2.0 was accepted as appropriate for RNA.
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3.6 Two-step Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR)
Reverse transcription and PCR were performed sequentially in two separate
reaction tubes using the Qiagen Two-Step RT-PCR kit (Qiagen, Valencia, CA). RNA
(4ug) was incubated for 5 minutes at 65°C then placed immediately on ice. Oligo-dT
(1 ul), 4 ul of 5x LongRange RT Buffer, 2 ul of dNTP Mix, 1 ul of LongRange
Reverse Transcriptase and 0.2 ul of LongRange RNase inhibitor were added to the
denatured RNA from each sample. RNase-free water was added to make the final
volume 20 ul. For synthesis of complementary DNA (cDNA), the mixes were
incubated for 90 minutes at 42°C and then heated at 85°C for 5 minutes to inactivate
the enzyme.
Long Range PCR Buffer (5ul of 10x), 2.5ul of dNTP mix, 2ul of forward primer
solutions, 2ul of reverse primer solutions, 10 ul of Q-Solution, 0.4 ul of LongRange
PCR Enzyme Mix and 26.1 ul of RNase-free water were thawed and used to make the
PCR mix, following the manufacturer’s protocol. Template cDNA (2 µl) were added
to each tube containing the reaction mix. For a simplified hot start, the tubes were
placed immediately into a thermal cycler that was preheated to 93°C for 3 min and the
cycling program started with 93˚C for 15 seconds, 62˚C for 30 seconds, and 68˚C for
1 minute.
Primers for MMP-9 were designed using PrimerQuest
(http://www.idtdna.com/Scitools/Applications/Primerquest/). Forward and reverse
primers were selected with the following criteria: optimal product size (~500), higher
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GC/AT ratio, and minimal probability of primer dimerization. The NCBI database
(http://www.ncbi.nlm.nih.gov/) was used to gather the complete sequence information
of each gene and to predict the PCR product sizes. Sequences of primers for LIV-1,
CDH-1, Snail, Slug and 18S Primers were obtained from previous published
literature. [56] The primers were ordered from Integrated DNA Technologies (IDT,
San Diego, CA). Before usage, a final primer concentration of 10 µM was prepared in
DEPC treated water. The primers used and their expected product sizes are shown in
Table 1.
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Table 1: Specific Primer Sequences
Gene

Sequence

LIV-1

Forward:

Product size Cycle numbers
161

27

462

35

284

30

282

30

504

30

84
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5’-GGTGATGGCCTGCACAATTTC-3’
Reverse:
5’-TTAACGGTCATGCCAGCCTTTAGTA-3’
CDH1

Forward:
5’-GTCATTGAGCCTGGCATTT-3’
Reverse:
5’-GCTTGAACTGCCGAAAAATC-3’

SNAI1

Forward:
5’-CCAGAGTCAGCCCTTAGTTC-3’
Reverse:
5’-AGGAGAGAGTCCAGAGGATG-3’

SNAI2

Forward:
5’-TCGGACCCACACATTACC-3’
Reverse:
5’-CTGGAGCAGAGGTTGTTAGC-3’

MMP-9

Forward:
5’-TACCACCTCGAACTTTGACAGCGA-3’
Reverse:
5’-ATCGCCAGTACTTCCCATCCTTGA-3’

18S

Forward:
5’-GCTTAATTTGACTCAACACGGGA-3’
Reverse:
5’-AGCTATCAATCTGTCAATCCT-3’
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In order to obtain an appropriate detection before reaching the plateau of the
PCR reaction, each pair of primers was tested for its optimal cycle number. The
thermo cycler was set to run until the cycle number of 35. At the end of 25, 27, 30 and
32 cycles, 5µl of sample was pipetted out into a 0.2 ml thin-wall PCR tube. The
samples were next separated on 1% agarose gel.

3.7 PCR Product Gel Electrophoresis
The amplified samples from two-step RT-PCR were separated by electrophoresis
through 1% agarose gels (0.5 g of agarose (Invitrogen, Carlsbad, CA)), in 50 ml TBE
buffer (Fisher Scientific, Pittsburgh, PA) containing 5 µl ethidium bromide (10
mg/ml). PCR amplified product (5 µl), 1 µl of 10 X loading dye, and 4 µl of distilled
water were mixed and loaded carefully into each lane of the 1% agarose gel. 100bp
DNA ladder (New England Biolabs, MA, USA) was added to one of the lanes and run
alongside the samples to validate the PCR product sizes. The gel was run at 120 volts
for 30 minutes. After the run was completed, the gel was visualized under UV light
using a ChemiDoc System (BioRad, Hercules, CA) and the bands quantified using
Quantity One Software (BioRad, Hercules, CA).

3.8 Protein Extraction
Cells grown in T-25 flasks were rinsed with 2 ml of PBS and detached with 2 ml
of 1XTE. The cell suspensions were transferred to 15 ml polypropylene tubes and
centrifuged at 1000 rpm for 3 minutes. The supernatant was removed and 50 µl of
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RIPA lysis buffer (Teknova, Hollister, CA) containing 30 µl/ml protease inhibitor
cocktail (Sigma, St. Louis, MO) was added to the pellets. The resuspended pellets
were transferred to pre-cooled microcentrifuge tubes after vortexing briefly. The tubes
were incubated with constant agitation on a platform shaker at 4˚C for 30 minutes.
Afterwards, the tubes were centrifuged at 10,000 rpm for 10 minutes at 4˚C to pellet
cell debris. The protein supernatants were transferred into pre-cooled tubes and stored
at -80˚C.

3.9 Protein Concentration Measurement
The BCA protein assay (Thermo Fisher Scientific, IL) was used for the
measurement of protein concentrations. Standards were prepared with albumin and
absorbance was measured at 562 nm. Protein concentrations were calculated with a
standard curve after absorbance was measured. RIPA buffer was used to make a five
times dilution of the sample solution.

3. 10 Western Blot
A 10% polyacrylamide resolving gel made with 1.5 M TrisHCl was cast and
milli-Q water was used to remove bubbles. After the gel polymerized for 1 hour, the
top layer of milli-Q water was removed before a 5% polyacrylamide stacking gel was
added and allowed to polymerize for 30 minutes.
Protein solution with 60 µg of protein and loading dye whose volume was half of
the protein solution were mixed and incubated at 95ºC for 10 minutes to denature the
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protein. The heated samples were loaded in the wells of the stacking gel alongside a
Precision plus Kaleidoscope Ladder (5 µl) protein standard (Bio-Rad Laboratories,
Hercules, CA). The gel was electrophoresed at room temperature in running buffer
(1X Tris/Glycine: 25 mM Tris, 192 mM Glycine, 0.1% SDS, pH 8.3) at 60 volts for
30min then switched to 150 volts for 1 hour.
The gel was removed from the glass plates. Since the molecular weights of
LIV-1 and CDH1 vary, 42 kD and 75 kD, respectively, the gel was divided into 2
parts along the 50 kD line and used for detecting the different proteins with different
primary antibodies. A piece of PVDF membrane was placed on each half of the gel
removing any bubbles between the gel and the membrane. The gel and membrane
were sandwiched between sponges and filter paper and placed in the transfer cassette.
The gel was placed close to the negative side. The transfer cassette was loaded in a
cartridge and placed in transfer buffer (100 mL of methanol, 700 mL of Milli-Q
water, and 100 mL of 10X Tris/Glycine (25 mM Tris, 192 mM glycine)). The transfer
was carried out for 2 hours at 250 mA at 4°C using the Mini Transblot Electrophoretic
Cell with a stir bar (Bio-Rad Laboratories, Hercules, CA).
After transfer, the membrane was removed from the transfer cassette and stained
with Ponceau S to ensure the integrity of the protein and the completeness of the
transfer. It was then blocked with 20 mL of blocking buffer (0.5% nonfat dry milk in
TBS/T [0.1% Tween-20 in Tris-buffered saline]) in a tray for one hour at room
temperature on a platform shaker. The blocking buffer was poured off and the
membrane was incubated with LIV-1 or CDH-1 primary antibodies (Santa Cruz
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Biotechnology, CA, USA) overnight on the shaker at 4 ºC. The dilution of LIV-1 and
CDH-1 rabbit polyclonal IgG antibodies used was 1:500. Both primary antibodies
were diluted in blocking buffer. The following day, the primary antibody solution was
removed and the membrane was washed three times with TBS / T (1% Tween-20) for
5 minutes each wash. After the washes, the goat anti-rabbit IgG-HRP secondary
antibody (Santa Cruz Biotechnology, CA, USA) was added (1:1000) and incubated
for 1 hour on the platform shaker. The membrane was rinsed with TBS twice before
adding the detection reagents.
Western Blotting Luminol Reagents (Santa Cruz Biotechnology, CA, USA) were
mixed together. The solution was poured onto the washed membrane and incubated
for 5 minutes with periodic shaking. The membrane was removed with tweezers and
was dragged with the protein side down along a piece of Kimwipe to remove excess
reagents before being inserted between sheet protectors. Light emissions from the
membrane were detected using the ChemiDoc System (BioRad, Hercules, CA) and
quantified using Quantity One Software (BioRad, Hercules, CA).
The membrane with LIV-1 primary antibodies was then incubated with Western
Re-Probe buffer (GBiosciences, MO) for 30 minutes to strip the LIV-1 primary
antibodies and then reprobed with β-Actin primary antibodies (Santa Cruz
Biotechnology, CA) using the same process as before.

3.11 MMP Proteolytic Assay
Non-target shRNA DU145 cells (5 x 104 ) and LIV-1 shRNA DU145 cells were
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plated into each well of a 96-well plate. Six hours after plating, the media were
removed and the cells rinsed with PBS. Cells were then incubated with 50 ul of
serum-free RPMI. After 20 hours, conditioned media were collected and centrifuged.
The supernatants were stored at -80°C before being used. Cell number was assessed
using the Cell-Titer Blue assay to make sure the cell growth rate would not influence
the MMP assay results.
A 10% polyacrylamide resolving gel embedded with 0.15% gelatin was made and
milli-Q water was used to remove bubbles. After the gel polymerized for 1hour, the
top layer of milli-Q water was removed and a 5% polyacrylamide stacking gel
without gelatin was added and allowed to polymerize for 30 minutes.
Conditioned media (15 ul) and 2 ul of loading dye were mixed and incubated at
room temperature for 10 minutes. The samples were loaded in the wells of stacking
gel and then electrophoresed in running buffer (1X Tris/Glycine: 25 mM Tris, 192
mM Glycine, 0.1% SDS, pH 8.3) at 120 volts for 90 minutes at room temperature.
After electrophoresis, the gel was rinsed with 1% Triton-100 3 times with 5
minutes each rinse to renature the MMP-9 protein. After incubation with the
developing buffer (50 mM Tris, 10 mM CaCl2 and 0.02% NaN3) for 20 hours at 37°C,
the gel was stained with 0.125% Coomassie brilliant blue (BioRad, Hercules, CA)
then destained until clear bands could be seen.
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3.12 Effects of DTPA on zinc distribution
Radioactive 65Zn (ZnCl2; 62.5 MBq/mg) was purchased from Perkin Elmer
(Shelton, CT). DTPA is an extracellular zinc chelator, which has an impact on the
zinc distribution between intracellular and extracellular zinc. In primary hepatocytes,
DTPA reduced the uptake of 65Zn from the medium and increased efflux from
prelabeled cells. However, in GH3 rat anterior pituitary tumor cells, DTPA reduced
the uptake of 65Zn from the medium, but promoted the retention of the isotope in the
prelabeled cells. [57] The isotope indicated the different effects of DTPA between
primary and transformed cells.
To study the effects of DTPA on the efflux of 65Zn in DU145 cells, cells were
plated in T-25 flasks and grown to about 75% confluency. The cells were then
prelabeled in growth media containing around 4.5 kcpm 65Zn for 48 hours.
Afterwards, the cells were provided with normal fresh media with or without 50uM
DTPA for another 48 hours. The media were then removed and the cells were rinsed
with PBS. Cells were detached with 1XTE. The 65Zn content of media, and cells were
quantified by gamma spectroscopy (Cobra II System, Packard, Meriden, CT).

3.13 Statistical Analyses
One way ANOVA with Bonferroni’s post hoc test (SPSS version 17.0) was used
to analyze data from all experiments. An α-level of p < 0.05 was considered
statistically significant.
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Chapter 4: Results
4.1 The Effects of EGF on LIV-1 and CDH1 Expression in DU145 and
LNCaP cells
The effects of 24 hours EGF treatment on LIV-1 and CDH1 expressions were
investigated in DU145 and LNCaP cells. EGF increased the protein expression of
LIV-1 by about 25% and decreased mRNA and protein expressions of CDH1 to
approximate 60% in both DU145 (Figure 1) and LNCaP (Figure 2) cells. No change
of LIV-1 mRNA was observed in either DU145 or LNCaP cells. Cells treated with
serum-free medium without EGF were used to normalize expression.

4.2 Knockdown of LIV-1 with shRNA in DU145 cells
MISSION® pLKO.1-puro vector plasmids with sequences specifically targeting
LIV-1 were used to knockdown LIV-1 expression in DU145 cells. MISSION®
pLKO.1-puro non-target shRNA control vectors were used as control. Compared to
the non-target shRNA control, LIV-1shRNA vectors decreased the LIV-1 mRNA and
protein expression in DU145 cells by around 40% (Figure 3). 18S RNA and β-actin
were chosen as the housekeeping gene and protein, respectively and were not affected
by LIV-1shRNA. Non-target shRNA transfected cells were used to normalize
expression.
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Figure 1:: Effects of EGF Treatment on LIV-1
LIV 1 and CDH1 mRNA and
protein in DU145 cells
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DU145 cells were treated with or without 10ng/ml EGF for 24 hours in serum-free
serum
media. (a)
LIV-1, CDH1 and 18S RNA contents were measured by RT-PCR
RT PCR with ethidium bromide stained
stain
agarose gel. (b) LIV-1,
1, CDH1 and β-actin
actin proteins were detected by Western blot
blo following
SDS-PAGE
PAGE gel separation of proteins. (c) Quantified bar graphs of LIV-11 and CDH1 mRNA
concentrations expressed relative to 18S RNA. (d) Quantified bar graphs of LIV-1
LIV and CDH1
protein concentrations expressed relative to β-actin.
C = cells treated without EGF used as control, E = cells treated with 10ng/ml EGF. The asterisk
indicate significant difference from the control (P<0.05).
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Figure 2:: Effects of EGF Treatment on LIV-1
LIV 1 and CDH1 mRNA and
protein in LNCaP cells
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LNCaP cells were treated with or without 10ng/ml for 24 hours EGF in serum-free
serum
media. (a) LIV-1,, CDH1 and 18S RNA contents were measured by RT-PC
PCR with ethidium
bromide stained agarose gel. (b) LIV-1, CDH1 and β-Actin
ctin proteins were detected by
Western blot following SDS-PAGE
SDS
gel separation of proteins. (c) Quantified bar graphs of
LIV-1 and CDH1 mRNA concentrations expressed relative to 18S RNA. (d) Quantified bar
graphs of LIV-1 and CDH1 expressed relative to β-Actin.
C = cells treated without EGF used as control, E = cells treated with 10ng/ml EGF. The
asterisk indicate significant difference from the control (P<0.05).
33

Figures 3:: Effects of shRNA Transfection on LIV-1
LIV and CDH1 Expression
in DU145 cells
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ctin proteins were detected by
Western blot following SDS-PAGE
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gel. (c) Quantified bar graphs of LIV-1
LIV and CDH1
mRNA concentrations expressed relative to 18S RNA. (d) Quantified bar graphs of LIV-1
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and CDH1 expressed relative to β-Actin.
N = cells transfected with non-targeting
non
shRNA, L = cells transfected with LIV-1
LIV
shRNA. The asterisk indicate significant difference from the control (P<0.05).
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4.3 The Effects of Knockdown on Snail, Slug and MMP-9 mRNA

Expression in DU145 cells
The effects of LIV-1 knockdown on Snail, Slug and MMP-9 mRNA expression
were investigated in DU145 cells (Figure 4). There was no change in Slug mRNA
expression in LIV-1 knockdown cells, compared with non-target shRNA transfected
cells. LIV-1 knockdown, however, decreased the expression of Snail mRNA by
approximately 60% whereas it decreased mRNA expression of MMP-9 by 40%.

4.4 Effects of EGF on DU145 and LNCaP cell proliferation
24 hours of 10ng/ml EGF treatment increased the cell growth rates of both
DU145 and LNCaP cells, by around 20% and 35%, respectively. The readings for
non-EGF treated cells were set up as 100% and the EGF-treated cells were compared
to the non-EGF treatment values. (Figure 5)

4.5 Effects of LIV-1 knockdown on DU145 cell proliferation
LIV-1shRNA knockdown in DU145 cells significantly inhibited cell growth to
around 85% at 48 hours, compared with non-target shRNA transfected cells. The
readings acquired at 6 hours after plating were set up as 100% for both non-target and
LIV-1 shRNA transfected DU145 cells. The readings at 24 hours and 48 hours were
compared to the 6 hour values. (Figure 6)
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Figure 4: Effects of LIV-1
LIV knockdown on Snail, Slug and MMP-9
MMP mRNA
expression in DU145 cells
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shRNA. The asterisk indicate significant difference from the control (P<0.05).
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Figure 5: Effects of EGF treatment on DU145 and LNCaP cell growth
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asterisk indicate significant difference from the control (P<0.05).

Figure 6: Effects of LIV-11 knockdown on DU145 cell growth
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assay. The reader values from 6 hours were used to normalize.
N = cells transfected with non-targeting
non
shRNA, L = cells transfected with LIV-1
LIV
shRNA. The asterisk indicate significant difference from the control (P<0.05).
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4.6 Effect of LIV-11 knockdown on proteolytic activity of MMP-9
MMP
Conditioned
onditioned media were collected to investigate the effect of LIV-1
LIV knockdown
on MMP-99 proteolytic activity. MMP-99 proteolytic activities were measured by
zymography. After electrophoresis, the MMP-9
MMP digests its substrate,
te, gelatin, which
was embedded in the SDS-PAGE
SDS
gel. Staining and destaining reveals the bands
where gelatin was digested by MMP-9.
MMP DU145 cells transfected
nsfected with LIV-1
LIV shRNA
appeared to have less MMP-9
MMP 9 proteolytic activity compared to those transfected with
non-target shRNA. However, the low intensity of the signal in the LIV-1
LIV shRNA
knockdown cells precluded the quantification of the data. (Figure 7)

Figure 7:: The effect of LIV-1
LIV knockdown on MMP-99 activity in DU145
cells
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plate. MMP-9 proteolytic activity were measured by
zymography. N = cells transfected with non-targeting
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4.7 Effect of DTPA on zinc distribution in DU145 cells
DU145 cells were used to explore the influence of reduced zinc availability on
zinc transport. When cells were pre-labeled
pre
with 65Zn, more 65Zn was retained in the
DTPA-treated
treated cells, indicating significantly decreased efflux of zinc. (Figure 8)
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Figure 8: The effect of 50uM DTPA on 65Zinc efflux in DU145 cells
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indicate
significant difference from the control (P<0.05).

39

Chapter 5: Discussion
In this study, the relationship between LIV-1 and CDH-1 expression and the
regulation of LIV-1 by EGF were examined in DU145 and LNCaP prostate cancer
cell lines. LNCaP and DU145 cells, represent androgen-dependent and
androgen-independent cells respectively. EGF has been shown to differentially
regulate CDH1 in estrogen receptor positive and estrogen receptor negative breast
cancer cell line. [56, 58] EGF treatment increased CDH1 expression in estrogen
receptor negative MDA-MB-231 breast cancer cells [56], while it decreased CDH1 in
MCF-7 estrogen receptor negative cells. [58]
Zinc is essential for various physiological processes and its concentrations are
under tight homeostatic control. [3] The two families of zinc transporters in humans,
ZnT and ZIP, are involved in zinc homeostasis. [15] They have also been reported to
have other roles in the cells. In fact, many of them are also involved in other
physiological functions. For example, ZnT2 functions in lactation, ZIP14 in the
hypozincemia of inflammation, ZIP6, ZIP7, and ZIP10 in metastatic breast cancer,
and ZnT8 in insulin processing and as an autoantigen in diabetes. [15] Therefore, zinc
transporters have been a major focus for scientific research. The peripheral zone
glandular secretory epithelium in the prostate accumulates extraordinarily high levels
of zinc and one most important factor in the development and progression of prostate
malignancy is the lost ability of the malignant cells to accumulate zinc. [10] Several
zinc transporters, such as ZIP1, ZIP2 and ZIP3, were down regulated in malignant
prostate cancer cells compared to normal prostate cells. [31, 32]
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The relationship between the zinc influx transporter, LIV-1, and cancer
progression has been investigated in breast cancer and prostate cancer. LIV-1 is
expressed widely, mainly in hormonally controlled tissues such as breast, prostate,
placenta, kidney, pituitary and corpus callosum. [27] LIV-1 has been identified as a
gene whose expression is stimulated by estrogen treatment in MCF-7 and ZR-75
breast cancer cells. [27] In zebrafish gastrula organizer, LIV-1 was shown to control
EMT by being a downstream target of the transcription factor STAT3. [21] Loss of
CDH1 expression appears to be strongly involved in EMT since there is a direct link
between lack of CDH1 production and loss of the epithelial phenotype. [41]
Down-regulation of CDH1 is associated with cell–cell dissociation and invasion in
various cancer models. [40] A reduced level of CDH1 is regarded as a characteristic
of EMT. [40]
One study found that interruption of EGFR signaling cascades results in an
inhibition of the growth of both androgen-responsive MDA Pca 2a, MDA Pca 2b and
LNCaP cells and androgen-independent DU145 and PC3 prostate cancer cells. This
was accompanied by a blockade of the progression from G1 into S phase. [59] EGF
treatment could activate the EGFR signaling pathway and stimulate cell growth. In
the current study, EGF treatment significantly stimulated cell proliferation rates of
both DU145 and LNCaP after 24 hours. Suppressed cell growth by LIV-1 knockdown
in DU145 was also found in our study. In HeLa cells, LIV-1 down-regulation also
inhibited cell growth. [60] EGF treatment induced LIV-1 and cell growth, but it is
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unclear, to which extent, the increased cell growth by EGF is due to the greater LIV-1
protein expression by EGF.
In this study, we investigated whether EGF regulated CDH1 through LIV-1 in
prostate cancer cells. EGF treatment did not alter LIV-1 mRNA expression. However,
at the protein level, EGF did induce LIV-1. The induction of LIV-1 protein expression
but not mRNA expression by EGF indicated post-transcriptional regulation. Effects of
EGF on post-transcriptional regulation and protein turnover have been reported in
several studies. [61, 62] EGF regulation of EGFR mRNA and protein in human
prostate cancer cell lines was found to occur at multiple transcriptional and
post-transcriptional levels. EGF regulated EGFR protein turnover by inducing rapid
disappearance of EGFR protein in LNCaP and DU145 cells with a half-life of
approximate 120 min, compared to approximate 5 h in control cells. [62] Another
example is ADAM17, which is a transmembrane metalloprotease involved in the
proteolytic release of the extracellular domain of many cell surface molecules, a
process known as ectodomain shedding. EGF treatment led to a marked increase in
the protein levels of ADAM17, but did not affect the levels of the ADAM17 mRNA.
It did not affect the ADAM17 protein synthesis but increased the maturation of the
ADAM17 protein and also increased the protein half life. [61] An investigation in
human breast cancer patients found that LIV-1 mRNA and protein expression levels
are weakly correlated in their tumors, indicating posttranscriptional regulations in
vivo. [33] The up-regulation of LIV-1 protein expression with no change in mRNA
concentrations in our study suggested posttranscriptional regulation of LIV-1 by EGF
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in prostate cancer cells.
Both mRNA and protein levels of CDH1 were measured in the same cells in this
study. It was found that EGF repressed the expression of CDH1 at both mRNA and
protein levels, raising the possibility that the expression of CDH1 might be down
regulated by LIV-1. Knockdown of LIV-1 increased CDH1 expression again
demonstrating a negative correlation between LIV-1 and CDH1 expressions.
We found successful knockdown of LIV-1 in DU145 was sufficient to increase
the CDH1 amount. CDH1 repressors, Snail and Slug, have been proposed as targets of
LIV-1 in human cervical cancer cell line HeLa. [60] Through stimulating Snail or
Slug, LIV-1 was proposed to have a negative effect on the expression of CDH1.
However, LIV-1 knockdown increased Slug and decreased CDH1 expression in
MDA-MB-231 breast cancer cells, while it did not alter Snail expression. [56] In this
study, we found decreased mRNA expressions of Snail, but not Slug, in LIV-1
knockdown cells. These results suggested that Snail may mediate the relationship
between LIV-1 and CDH1 in prostate cancer cells.
MMP-9 is known to play a role in angiogenesis, tumor growth and metastasis.
[48] Overexpressed LIV-1 in prostate cancer cells, ARCaP, through transfection
resulted in elevated MMP-9 proteolytic enzyme activity and decreased CDH1
expression. [35] The ability to stimulate MMP-9 proteolytic enzyme activity has been
proposed to be another pathway by which LIV-1 promoted EMT transition. However,
the relationship between MMP-9 and CDH1 is still not clear. One study in epithelial
ovarian cancer cells showed that transient expression of MMP-9 was sufficient to
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reduce CDH1 levels. [52] Incubation of epithelial ovarian carcinoma cells with
exogenous MMP-9 increased shedding of the CDH1 ectodomain, suggesting
posttranslational modification of CDH1 function by MMP-9. [53] However, some
other studies have indicated that CDH1 might down regulate MMP-9. In highly
invasive bronchial BZR tumor cells, CDH1 expression is absent. Compared with
CDH1 negative clones, MMP-9 decreased both at the mRNA and at the protein levels
in transfected CDH1-positive clones. [55] Decreased MMP-9 mRNA expression and
proteolytic activity were observed in LIV-1 knockdown DU145 cells. It appears that
LIV-1 influences the cells migratory and invasive properties through both CDH1 and
MMP-9.
Normal cells and cancer cells responded to DTPA, as an extracellular zinc
chelator, in different ways. DTPA promoted efflux of 65Zn from rat primary
hepatocytes and pituitary cells, while it increased its retention in rat hepatoma and
anterior pituitary tumor cells. [57] More zinc was retained in the DTPA-treated
DU145 cells in our study, suggesting that even though prostate cancer cells lose their
ability to accumulate high zinc, zinc deprivation still may induce its ability to
accumulate zinc, in common with other cancer cell lines.
Post-transcriptional regulation of LIV-1 by EGF was found in this study. More
work can be done to look into the precise mode of this regulation, for instance
whether EGF increases the translation of LIV-1 or increases protein stability. In
addition, it would be useful to show at what time point the LIV-1 and CDH1
expression starts to show alterations in response to EGF. Other growth factors, such
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as insulin growth factor may also be able to regulate CDH1 through LIV-1.
In summary, as illustrated in Figure 9, this study showed that LIV-1 was involved
in EGF-dependent down-regulation of CDH1 and knockdown of LIV-1 was sufficient
to induce CDH1 levels in the absence of EGF by repressing CDH1 repressor Snail in
prostate cancer cells. Another tumor metastasis marker MMP-9 was also inhibited
with the LIV-1 knockdown, which confirmed the role of LIV-1 in prostate cancer
progression.
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Figure 9: Schematic illustrating the relationship between LIV-1 and CDH1
in current study
EGF

LIV-1(post-transcriptioal induction)
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